Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

Donskov, F
Michaelson, MD
Puzanov, I
Davis, MP
Bjarnason, GA
Motzer, RJ
Goldstein, D
Lin, X
Cohen, DP
Wiltshire, R
Rini, BI

Open PDF

Open link

Publication date

December 2015

DOI

10.1038/bjc.2015.368

Publisher

Springer Science and Business Media LLC

Abstract

Background:Metastatic renal cell carcinoma (mRCC) prognostic models may be improved by incorporating treatment-induced toxicities.Methods:In sunitinib-treated mRCC patients (N=770), baseline prognostic factors and treatment-induced toxicities (hypertension (systolic blood pressure ≥140 mm Hg), neutropenia (grade ≥2), thrombocytopenia (grade ≥2), hand-foot syndrome (grade >0), and asthenia/fatigue (grade >0)) were analysed in multivariate analyses of progression-free survival (PFS) and overall survival (OS) end points.Results:On-treatment neutropenia and hypertension were associated with longer PFS (P=0.0276 and P<0.0001, respectively) and OS (P=0.0014 and P<0.0001, respectively), independent of baseline prognostic factors, including Interna...